Emily Tribulski

Emily Tribulski is an associate in Goodwin’s Technology and Life Sciences groups and a member of the firm’s Life Sciences Regulatory & Compliance practice. She counsels pharmaceutical, biologic, medical device, digital health, and consumer product companies on FDA regulatory compliance issues, including drug and device development issues, interactions with FDA, internal corporate investigations, and responding to FDA inspection observations and enforcement actions. Emily also advises FDA-regulated entities in connection with corporate transactions, offerings and licensing matters.

• Analyzes a variety of legal and regulatory requirements on matters involving product development and marketing approval for drugs, biologics, devices and diagnostics
• Conducts regulatory due diligence and provides support for M&A transactions, private equity investments, individual investments and licensing deals involving FDA-regulated entities
• Provides extensive review of corporate communications and regulatory disclosures in securities filings for pharmaceutical and medical device companies across the preclinical to commercial stages, including for corporate presentations and press releases

Recent notable matters include:

• Represented underwriters in a public follow-on offering for CymaBay Therapeutics, a clinical-stage biopharmaceutical company 
• Represented Arlington Capital Partners in its carve-out acquisition of the avian vaccine services business of Charles River Laboratories, Inc. to form a new company, AVS Bio
• Represented Yumanity Therapeutics, Inc. in its reverse merger with Kineta, Inc. 
• Represented underwriters in a public follow-on offering for X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company
• Represented Frazier Lifesciences Acquisition Corporation in its business combination with NewAmsterdam Pharma Holding N.V. (NAP), pursuant to which NAP became a publicly traded company via deSPAC transaction
• Represented underwriters in Acrivon Therapeutics’ IPO
• Represented Akero Therapeutics, Inc. in an upsized public follow-on offering
• Represented Relay Therapeutics, Inc. in a public offering of common stock
• Represented TA Associates Management, L.P. in its acquisition of nearly 100% of the equity interests of Advantice Health Holdings, LLC, the indirect parent company of Advantice Health, LLC
• Represented Amylyx Pharmaceuticals, Inc. in its $216 million IPO

Emily is a member of the Food and Drug Law Institute (FDLI).

Emily was a summer associate at Goodwin in 2020. During law school, Emily served as a law clerk at the United States Attorneys’ Office for the District of Columbia and was a student attorney for Duke Law’s Health Justice Clinic. She also served as the President of the Duke Bar Association, as an Executive Editor of Law & Contemporary Problems, and as a Content Editor of Duke Law & Technology Review.

Prior to law school, Emily was a senior research analyst for the Office of the Governor of New Jersey.

Emily’s recent publications include:

• Author, “Look What You Made Her Do: How Swift, Streaming, and Social Media Can Increase Artists’ Bargaining Power,” 19 Duke L. & Tech. Rev. 91, 2021
• Co-Author, “Things for Pharma and Biotech Companies to Watch in the Cures 2.0 Proposed Legislation - Life Sciences Perspectives,” JDSupra, November 22, 2021
• Co-Author, “FDA Issues Guiding Principles for Good Machine Learning Practice for Medical Device Development - Life Sciences Perspectives,” National Law Review, October 29, 2021
• Co-Author, “Real-World Evidence: Challenges and Opportunities During COVID-19,” Goodwin Life Sciences Perspectives, July 29, 2020